#128 – IDWeek 2025 Recap

#127 – What’s Pneu in Community-Acquired Pneumonia Part 2

#126 – What’s the Microbiome Gut to Do with It

#125 – The Scariest and Baddest: Burkholderia, Achromobacter, and Elizabethkingia

#124 – Dosing Consult: Cefepime

#123 – Rol del Farmacéutico en los PROA en América Latina

#122 – The Role of The Pharmacist in Antimicrobial Stewardship in Latin America

#121 – Finding BALANCE in Antibiotic Durations: The BALANCE Trial

#120 – What’s Pneu in Community-Acquired Pneumonia

#119 – Dosing Consult: Fluconazole

#118 – Hot Topics: What You May Have Missed in Infectious Diseases 2024-2025 (LIVE from MAD-ID)

#117 – Amnio-Oh-No You Didn’t: Modernizing Antimicrobial Regimens for Intraamniotic Infections

#116 – SNAP Out of It: Rethinking Antistaphylococcal Penicillins for S. Aureus Bacteremia – The SNAP Trial PSSA/MSSA Results

#115 – Silver Lining of Shortages: Blood Culture Best Practices

#114 – Dosing Consult: Amoxicillin/Clavulanate

#113 – Ask ChatGPT: The Role of AI in Healthcare

#112 – Say It Ain't Steno: Stenotrophomonas maltophilia Review

#111 – Dosing Consult: Rifampin Part 2

#110 – A Bone to Pick: Biofilm Busters for Prosthetic Joint Infections

#109 – IDWeek 2024 Recap: Practice Changing Papers and ID Potpourri